HOME >> BIOLOGY >> NEWS
Turning the tables in chemistry

Waltham, MAWhat do glowing veggies have to do with a career in science" It just so happens that electrified pickles swimming in metal ions are one example of the type of undergraduate chemistry class demonstration that helps make a future in science a bright possibility, rather than a total turn-off, for many students.

In a commentary in this months Nature Chemical Biology, Brandeis University and Howard Hughes Medical Institute (HHMI) Professor Irving Epstein outlines a gathering storm clouding the future of U.S. science and prescribes a series of strategies to help avert a looming national crisis. Epstein says the continued success of U.S. science is seriously threatened by the fact that increasing numbers of undergraduates, particularly the disadvantaged, are writing off a career in science.

Why? Many students find introductory science, and chemistry in particular, both difficult and dull the way it is conventionally taught at the college level, discouraging many potential scientists before they ever have the chance to get hooked on science.

Anyone who teaches an introductory science course at one of this countrys elite universities is familiar with the sea of white faces he or she encounters, and the tendency of that ocean to whiten even more as the semester progresses and as one moves up the ladder of courses, writes Epstein, who last year won $1 million from HHMI to revamp introductory chemistry at Brandeis with an eye to luringand retainingmore students in science, particularly disadvantaged ones.

We need to ask ourselves why science is unattractive to so many students, particularly (but by no means exclusively), to underrepresented minority students, writes Epstein. He believes that conventional science teaching and passive learning are primary culprits, because they rely too heavily on lecturing as well as unrelated and unexciting laboratory experiments.

Epstein proposes a variety of strategies aimed at
'"/>

Contact: Laura Gardner
gardner@brandeis.edu
781-736-4204
Brandeis University
7-Jun-2007


Page: 1 2

Related biology news :

1. Turning a cellular sentinel into a cancer killer
2. Turning green into yellow
3. Turning sensation into perception
4. Turning viruses into allies against cancer
5. Food safety begins as vegetables grow
6. Researcher focuses on pros, cons of antioxidants from fruits and vegetables
7. Nutrients in certain vegetables may provide cancer-fighting benefit
8. Vegetables, like people, urged to live up to potential
9. Healthy fruits, vegetables highlight joint medical, agricultural research meet in Texas
10. Leafy green vegetables may help keep brains sharp through aging
11. Aloe vera coating may prolong freshness, safety of fruits and vegetables

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Turning the tables chemistry

(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: